Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 392

1.

A phase II study evaluating the efficacy of zoledronic acid in prevention of aromatase inhibitor-associated musculoskeletal symptoms: the ZAP trial.

Santa-Maria CA, Bardia A, Blackford AL, Snyder C, Connolly RM, Fetting JH, Hayes DF, Jeter SC, Miller RS, Nguyen A, Quinlan K, Rosner GL, Slater S, Storniolo AM, Wolff AC, Zorzi J, Henry NL, Stearns V.

Breast Cancer Res Treat. 2018 May 11. doi: 10.1007/s10549-018-4811-1. [Epub ahead of print]

PMID:
29752687
2.

Paclitaxel Plasma Concentration After the First Infusion Predicts Treatment-Limiting Peripheral Neuropathy.

Hertz DL, Kidwell KM, Vangipuram K, Li F, Pai MP, Burness M, Griggs JJ, Schott AF, Van Poznak C, Hayes DF, Smith EM, Henry NL.

Clin Cancer Res. 2018 Apr 27. pii: clincanres.0656.2018. doi: 10.1158/1078-0432.CCR-18-0656. [Epub ahead of print]

PMID:
29703818
3.

Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review.

Merker JD, Oxnard GR, Compton C, Diehn M, Hurley P, Lazar AJ, Lindeman N, Lockwood CM, Rai AJ, Schilsky RL, Tsimberidou AM, Vasalos P, Billman BL, Oliver TK, Bruinooge SS, Hayes DF, Turner NC.

J Clin Oncol. 2018 Mar 5:JCO2017768671. doi: 10.1200/JCO.2017.76.8671. [Epub ahead of print]

PMID:
29504847
4.

Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review.

Merker JD, Oxnard GR, Compton C, Diehn M, Hurley P, Lazar AJ, Lindeman N, Lockwood CM, Rai AJ, Schilsky RL, Tsimberidou AM, Vasalos P, Billman BL, Oliver TK, Bruinooge SS, Hayes DF, Turner NC.

Arch Pathol Lab Med. 2018 Mar 5. doi: 10.5858/arpa.2018-0901-SA. [Epub ahead of print]

PMID:
29504834
5.

Breast-Cancer Recurrence after Stopping Endocrine Therapy.

Pan H, Gray R, Hayes DF; Early Breast Cancer Trialists’ Collaborative Group.

N Engl J Med. 2018 Mar 1;378(9):870-871. doi: 10.1056/NEJMc1715968. No abstract available.

6.

Impact of homologous recombination deficiency biomarkers on outcomes in patients with triple-negative breast cancer treated with adjuvant doxorubicin and cyclophosphamide (SWOG S9313).

Sharma P, Barlow WE, Godwin AK, Pathak H, Isakova K, Williams D, Timms KM, Hartman AR, Wenstrup RJ, Linden HM, Tripathy D, Hortobagyi GN, Hayes DF.

Ann Oncol. 2018 Mar 1;29(3):654-660. doi: 10.1093/annonc/mdx821.

PMID:
29293876
7.

Genome-wide meta-analyses identifies novel taxane-induced peripheral neuropathy-associated loci.

Sucheston-Campbell LE, Clay-Gilmour AI, Barlow WE, Budd GT, Stram DO, Haiman CA, Sheng X, Yan L, Zirpoli G, Yao S, Jiang C, Owzar K, Hershman D, Albain KS, Hayes DF, Moore HC, Hobday TJ, Stewart JA, Rizvi A, Isaacs C, Salim M, Gralow JR, Hortobagyi GN, Livingston RB, Kroetz DL, Ambrosone CB.

Pharmacogenet Genomics. 2018 Feb;28(2):49-55. doi: 10.1097/FPC.0000000000000318.

PMID:
29278617
8.

Precision Medicine and Testing for Tumor Biomarkers-Are All Tests Born Equal?

Hayes DF.

JAMA Oncol. 2017 Dec 14. doi: 10.1001/jamaoncol.2017.4018. [Epub ahead of print] No abstract available.

PMID:
29242914
9.

Streamlining Adverse Events Reporting in Oncology: An American Society of Clinical Oncology Research Statement.

Levit LA, Perez RP, Smith DC, Schilsky RL, Hayes DF, Vose JM.

J Clin Oncol. 2018 Feb 20;36(6):617-623. doi: 10.1200/JCO.2017.75.8193. Epub 2017 Dec 13. No abstract available.

PMID:
29236570
10.

Comprehensive Mutation and Copy Number Profiling in Archived Circulating Breast Cancer Tumor Cells Documents Heterogeneous Resistance Mechanisms.

Paoletti C, Cani AK, Larios JM, Hovelson DH, Aung K, Darga EP, Cannell EM, Baratta PJ, Liu CJ, Chu D, Yazdani M, Blevins AR, Sero V, Tokudome N, Thomas DG, Gersch C, Schott AF, Wu YM, Lonigro R, Robinson DR, Chinnaiyan AM, Bischoff FZ, Johnson MD, Park BH, Hayes DF, Rae JM, Tomlins SA.

Cancer Res. 2018 Feb 15;78(4):1110-1122. doi: 10.1158/0008-5472.CAN-17-2686. Epub 2017 Dec 12.

PMID:
29233927
11.

Disseminated breast tumour cells: biological and clinical meaning.

Pantel K, Hayes DF.

Nat Rev Clin Oncol. 2018 Mar;15(3):129-131. doi: 10.1038/nrclinonc.2017.174. Epub 2017 Nov 21. No abstract available.

PMID:
29158590
12.

20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years.

Pan H, Gray R, Braybrooke J, Davies C, Taylor C, McGale P, Peto R, Pritchard KI, Bergh J, Dowsett M, Hayes DF; EBCTCG.

N Engl J Med. 2017 Nov 9;377(19):1836-1846. doi: 10.1056/NEJMoa1701830.

13.

Reply to 'The St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology' by Kirova et al.

Dubsky P, Curigliano G, Burstein HJ, Winer EP, Gnant M, Loibl S, Colleoni M, Regan MM, Piccart-Gebhart M, Senn HJ, Thürlimann B; Panel Members of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017, André F, Baselga J, Bergh J, Bonnefoi H, Brucker SY, Cardoso F, Carey L, Ciruelos E, Cuzick J, Denkert C, Di Leo A, Ejlertsen B, Francis P, Galimberti V, Garber J, Gulluoglu B, Goodwin P, Harbeck N, Hayes DF, Huang CS, Huober J, Khaled H, Jassem J, Jiang Z, Karlsson P, Morrow M, Orecchia R, Osborne KC, Pagani O, Partridge AH, Pritchard K, Ro J, Rutgers EJT, Sedlmayer F, Semiglazov V, Shao Z, Smith I, Toi M, Tutt A, Viale G, Watanabe T, Whelan TJ, Xu B.

Ann Oncol. 2018 Jan 1;29(1):281-282. doi: 10.1093/annonc/mdx543. No abstract available.

PMID:
29045519
14.

Androgen receptor as a mediator and biomarker of radioresistance in triple-negative breast cancer.

Speers C, Zhao SG, Chandler B, Liu M, Wilder-Romans K, Olsen E, Nyati S, Ritter C, Alluri PG, Kothari V, Hayes DF, Lawrence TS, Spratt DE, Wahl DR, Pierce LJ, Feng FY.

NPJ Breast Cancer. 2017 Aug 18;3:29. doi: 10.1038/s41523-017-0038-2. eCollection 2017.

15.

De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017.

Curigliano G, Burstein HJ, P Winer E, Gnant M, Dubsky P, Loibl S, Colleoni M, Regan MM, Piccart-Gebhart M, Senn HJ, Thürlimann B; St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017, André F, Baselga J, Bergh J, Bonnefoi H, Y Brucker S, Cardoso F, Carey L, Ciruelos E, Cuzick J, Denkert C, Di Leo A, Ejlertsen B, Francis P, Galimberti V, Garber J, Gulluoglu B, Goodwin P, Harbeck N, Hayes DF, Huang CS, Huober J, Hussein K, Jassem J, Jiang Z, Karlsson P, Morrow M, Orecchia R, Osborne KC, Pagani O, Partridge AH, Pritchard K, Ro J, Rutgers EJT, Sedlmayer F, Semiglazov V, Shao Z, Smith I, Toi M, Tutt A, Viale G, Watanabe T, Whelan TJ, Xu B.

Ann Oncol. 2017 Aug 1;28(8):1700-1712. doi: 10.1093/annonc/mdx308.

PMID:
28838210
16.

Integrative clinical genomics of metastatic cancer.

Robinson DR, Wu YM, Lonigro RJ, Vats P, Cobain E, Everett J, Cao X, Rabban E, Kumar-Sinha C, Raymond V, Schuetze S, Alva A, Siddiqui J, Chugh R, Worden F, Zalupski MM, Innis J, Mody RJ, Tomlins SA, Lucas D, Baker LH, Ramnath N, Schott AF, Hayes DF, Vijai J, Offit K, Stoffel EM, Roberts JS, Smith DC, Kunju LP, Talpaz M, Cieślik M, Chinnaiyan AM.

Nature. 2017 Aug 17;548(7667):297-303. doi: 10.1038/nature23306. Epub 2017 Aug 2.

PMID:
28783718
17.

Elevated S100A8 protein expression in breast cancer cells and breast tumor stroma is prognostic of poor disease outcome.

Miller P, Kidwell KM, Thomas D, Sabel M, Rae JM, Hayes DF, Hudson BI, El-Ashry D, Lippman ME.

Breast Cancer Res Treat. 2017 Nov;166(1):85-94. doi: 10.1007/s10549-017-4366-6. Epub 2017 Jul 17.

PMID:
28717852
18.

Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer.

Ma CX, Bose R, Gao F, Freedman RA, Telli ML, Kimmick G, Winer E, Naughton M, Goetz MP, Russell C, Tripathy D, Cobleigh M, Forero A, Pluard TJ, Anders C, Niravath PA, Thomas S, Anderson J, Bumb C, Banks KC, Lanman RB, Bryce R, Lalani AS, Pfeifer J, Hayes DF, Pegram M, Blackwell K, Bedard PL, Al-Kateb H, Ellis MJC.

Clin Cancer Res. 2017 Oct 1;23(19):5687-5695. doi: 10.1158/1078-0432.CCR-17-0900. Epub 2017 Jul 5.

PMID:
28679771
19.

Making a Difference in Cancer Care With You.

Hayes DF.

J Clin Oncol. 2017 Aug 20;35(24):2723-2728. doi: 10.1200/JCO.2017.74.5703. Epub 2017 Jul 5. No abstract available.

PMID:
28678666
20.

Variable aromatase inhibitor plasma concentrations do not correlate with circulating estrogen concentrations in post-menopausal breast cancer patients.

Hertz DL, Speth KA, Kidwell KM, Gersch CL, Desta Z, Storniolo AM, Stearns V, Skaar TC, Hayes DF, Henry NL, Rae JM.

Breast Cancer Res Treat. 2017 Oct;165(3):659-668. doi: 10.1007/s10549-017-4346-x. Epub 2017 Jun 22.

PMID:
28643023
21.

American Society of Clinical Oncology Strategic Plan for Increasing Racial and Ethnic Diversity in the Oncology Workforce.

Winkfield KM, Flowers CR, Patel JD, Rodriguez G, Robinson P, Agarwal A, Pierce L, Brawley OW, Mitchell EP, Head-Smith KT, Wollins DS, Hayes DF.

J Clin Oncol. 2017 Aug 1;35(22):2576-2579. doi: 10.1200/JCO.2017.73.1372. Epub 2017 May 1.

PMID:
28459634
22.

Prospective assessment of patient-reported outcomes and estradiol and drug concentrations in patients experiencing toxicity from adjuvant aromatase inhibitors.

Kadakia KC, Kidwell KM, Seewald NJ, Snyder CF, Storniolo AM, Otte JL, Flockhart DA, Hayes DF, Stearns V, Henry NL.

Breast Cancer Res Treat. 2017 Jul;164(2):411-419. doi: 10.1007/s10549-017-4260-2. Epub 2017 Apr 27.

PMID:
28451964
23.

Associations Between Patient and Anthropometric Characteristics and Aromatase Inhibitor Discontinuation.

Henry NL, Speth K, Lintermans A, Kidwell KM, Carlson R, Hayes DF, Neven P.

Clin Breast Cancer. 2017 Aug;17(5):350-355.e4. doi: 10.1016/j.clbc.2017.03.002. Epub 2017 Mar 11.

PMID:
28365336
24.

Targeted Degradation of BET Proteins in Triple-Negative Breast Cancer.

Bai L, Zhou B, Yang CY, Ji J, McEachern D, Przybranowski S, Jiang H, Hu J, Xu F, Zhao Y, Liu L, Fernandez-Salas E, Xu J, Dou Y, Wen B, Sun D, Meagher J, Stuckey J, Hayes DF, Li S, Ellis MJ, Wang S.

Cancer Res. 2017 May 1;77(9):2476-2487. doi: 10.1158/0008-5472.CAN-16-2622. Epub 2017 Feb 16.

25.

Effects of exemestane and letrozole therapy on plasma concentrations of estrogens in a randomized trial of postmenopausal women with breast cancer.

Robarge JD, Desta Z, Nguyen AT, Li L, Hertz D, Rae JM, Hayes DF, Storniolo AM, Stearns V, Flockhart DA, Skaar TC, Henry NL.

Breast Cancer Res Treat. 2017 Feb;161(3):453-461. doi: 10.1007/s10549-016-4077-4. Epub 2016 Dec 9.

26.

Maternal Embryonic Leucine Zipper Kinase (MELK) as a Novel Mediator and Biomarker of Radioresistance in Human Breast Cancer.

Speers C, Zhao SG, Kothari V, Santola A, Liu M, Wilder-Romans K, Evans J, Batra N, Bartelink H, Hayes DF, Lawrence TS, Brown PH, Pierce LJ, Feng FY.

Clin Cancer Res. 2016 Dec 1;22(23):5864-5875. Epub 2016 May 25.

27.

The lncRNA landscape of breast cancer reveals a role for DSCAM-AS1 in breast cancer progression.

Niknafs YS, Han S, Ma T, Speers C, Zhang C, Wilder-Romans K, Iyer MK, Pitchiaya S, Malik R, Hosono Y, Prensner JR, Poliakov A, Singhal U, Xiao L, Kregel S, Siebenaler RF, Zhao SG, Uhl M, Gawronski A, Hayes DF, Pierce LJ, Cao X, Collins C, Backofen R, Sahinalp CS, Rae JM, Chinnaiyan AM, Feng FY.

Nat Commun. 2016 Sep 26;7:12791. doi: 10.1038/ncomms12791.

28.

Addressing Administrative and Regulatory Burden in Cancer Clinical Trials: Summary of a Stakeholder Survey and Workshop Hosted by the American Society of Clinical Oncology and the Association of American Cancer Institutes.

Vose JM, Levit LA, Hurley P, Lee C, Thompson MA, Stewart T, Hofacker J, Bruinooge SS, Hayes DF.

J Clin Oncol. 2016 Nov 1;34(31):3796-3802. doi: 10.1200/JCO.2016.69.6781. No abstract available.

PMID:
27601549
29.

Affordable Care, Basic Economics, and the Customer/Patient.

Hayes DF.

J Am Coll Radiol. 2016 Dec;13(12 Pt A):1474-1476. doi: 10.1016/j.jacr.2016.06.042. Epub 2016 Aug 26. No abstract available.

PMID:
27576134
30.

Epithelial Cell Adhesion Molecule Expression in Canine Tumours.

Thamm DH, Hayes DF, Meuten T, Laver T, Thomas DG.

J Comp Pathol. 2016 Nov;155(4):299-304. doi: 10.1016/j.jcpa.2016.07.010. Epub 2016 Aug 24.

PMID:
27567927
31.

Polymorphisms in drug-metabolizing enzymes and steady-state exemestane concentration in postmenopausal patients with breast cancer.

Hertz DL, Kidwell KM, Seewald NJ, Gersch CL, Desta Z, Flockhart DA, Storniolo AM, Stearns V, Skaar TC, Hayes DF, Henry NL, Rae JM.

Pharmacogenomics J. 2017 Dec;17(6):521-527. doi: 10.1038/tpj.2016.60. Epub 2016 Aug 23.

32.

ESR1 and PGR polymorphisms are associated with estrogen and progesterone receptor expression in breast tumors.

Hertz DL, Henry NL, Kidwell KM, Thomas D, Goddard A, Azzouz F, Speth K, Li L, Banerjee M, Thibert JN, Kleer CG, Stearns V, Hayes DF, Skaar TC, Rae JM.

Physiol Genomics. 2016 Sep 1;48(9):688-98. doi: 10.1152/physiolgenomics.00065.2016. Epub 2016 Aug 19.

33.

Phase II studies of two different schedules of dasatinib in bone metastasis predominant metastatic breast cancer: SWOG S0622.

Schott AF, Barlow WE, Van Poznak CH, Hayes DF, Moinpour CM, Lew DL, Dy PA, Keller ET, Keller JM, Hortobagyi GN.

Breast Cancer Res Treat. 2016 Aug;159(1):87-95. doi: 10.1007/s10549-016-3911-z. Epub 2016 Jul 30.

34.

SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer.

Nahleh ZA, Barlow WE, Hayes DF, Schott AF, Gralow JR, Sikov WM, Perez EA, Chennuru S, Mirshahidi HR, Corso SW, Lew DL, Pusztai L, Livingston RB, Hortobagyi GN.

Breast Cancer Res Treat. 2016 Aug;158(3):485-95. doi: 10.1007/s10549-016-3889-6. Epub 2016 Jul 8.

35.

Innovations in American Society of Clinical Oncology Practice Guideline Development.

Somerfield MR, Bohlke K, Browman GP, Denduluri N, Einhaus K, Hayes DF, Khorana AA, Miller RS, Mohile SG, Oliver TK, Ortiz E, Lyman GH.

J Clin Oncol. 2016 Sep 10;34(26):3213-20. doi: 10.1200/JCO.2016.68.3524. Epub 2016 Jul 5.

PMID:
27382097
36.

Considerations for Implementation of Cancer Molecular Diagnostics Into Clinical Care.

Hayes DF.

Am Soc Clin Oncol Educ Book. 2016;35:292-6. doi: 10.14694/EDBK_160236.

37.

Analytical validation of a standardized scoring protocol for Ki67: phase 3 of an international multicenter collaboration.

Leung SCY, Nielsen TO, Zabaglo L, Arun I, Badve SS, Bane AL, Bartlett JMS, Borgquist S, Chang MC, Dodson A, Enos RA, Fineberg S, Focke CM, Gao D, Gown AM, Grabau D, Gutierrez C, Hugh JC, Kos Z, Lænkholm AV, Lin MG, Mastropasqua MG, Moriya T, Nofech-Mozes S, Osborne CK, Penault-Llorca FM, Piper T, Sakatani T, Salgado R, Starczynski J, Viale G, Hayes DF, McShane LM, Dowsett M.

NPJ Breast Cancer. 2016 May 18;2:16014. doi: 10.1038/npjbcancer.2016.14. eCollection 2016.

38.

Heterogeneous estrogen receptor expression in circulating tumor cells suggests diverse mechanisms of fulvestrant resistance.

Paoletti C, Larios JM, Muñiz MC, Aung K, Cannell EM, Darga EP, Kidwell KM, Thomas DG, Tokudome N, Brown ME, Connelly MC, Chianese DA, Schott AF, Henry NL, Rae JM, Hayes DF.

Mol Oncol. 2016 Aug;10(7):1078-85. doi: 10.1016/j.molonc.2016.04.006. Epub 2016 Apr 29.

39.

Comparative analysis of circulating tumor DNA stability In K3EDTA, Streck, and CellSave blood collection tubes.

Kang Q, Henry NL, Paoletti C, Jiang H, Vats P, Chinnaiyan AM, Hayes DF, Merajver SD, Rae JM, Tewari M.

Clin Biochem. 2016 Dec;49(18):1354-1360. doi: 10.1016/j.clinbiochem.2016.03.012. Epub 2016 Apr 27.

PMID:
27129799
40.

Patient-Reported Outcomes and Early Discontinuation in Aromatase Inhibitor-Treated Postmenopausal Women With Early Stage Breast Cancer.

Kadakia KC, Snyder CF, Kidwell KM, Seewald NJ, Flockhart DA, Skaar TC, Desta Z, Rae JM, Otte JL, Carpenter JS, Storniolo AM, Hayes DF, Stearns V, Henry NL.

Oncologist. 2016 May;21(5):539-46. doi: 10.1634/theoncologist.2015-0349. Epub 2016 Mar 23.

41.

Circulating Tumor Cells.

Paoletti C, Hayes DF.

Adv Exp Med Biol. 2016;882:235-58. doi: 10.1007/978-3-319-22909-6_10. Review.

PMID:
26987538
42.

Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Summary.

Harris LN, Ismaila N, McShane LM, Hayes DF.

J Oncol Pract. 2016 Apr;12(4):384-9. doi: 10.1200/JOP.2016.010868. Epub 2016 Mar 8. No abstract available.

PMID:
26957642
43.

Clinical predictors of long-term survival in HER2-positive metastatic breast cancer.

Murthy P, Kidwell KM, Schott AF, Merajver SD, Griggs JJ, Smerage JD, Van Poznak CH, Wicha MS, Hayes DF, Henry NL.

Breast Cancer Res Treat. 2016 Feb;155(3):589-95. doi: 10.1007/s10549-016-3705-3. Epub 2016 Feb 13.

44.

Fulvestrant decreases anastrozole drug concentrations when taken concurrently by patients with metastatic breast cancer treated on SWOG study S0226.

Hertz DL, Barlow WE, Kidwell KM, Albain KS, Vandenberg TA, Dakhil SR, Tirumali NR, Livingston RB, Gralow J, Hayes DF, Hortobagyi GN, Mehta RS, Rae JM.

Br J Clin Pharmacol. 2016 Jun;81(6):1134-41. doi: 10.1111/bcp.12904. Epub 2016 Apr 8.

45.

Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline.

Harris LN, Ismaila N, McShane LM, Andre F, Collyar DE, Gonzalez-Angulo AM, Hammond EH, Kuderer NM, Liu MC, Mennel RG, Van Poznak C, Bast RC, Hayes DF; American Society of Clinical Oncology.

J Clin Oncol. 2016 Apr 1;34(10):1134-50. doi: 10.1200/JCO.2015.65.2289. Epub 2016 Feb 8. Review.

46.

Cognitive dysfunction and symptom burden in women treated for breast cancer: a prospective behavioral and fMRI analysis.

Jung MS, Zhang M, Askren MK, Berman MG, Peltier S, Hayes DF, Therrien B, Reuter-Lorenz PA, Cimprich B.

Brain Imaging Behav. 2017 Feb;11(1):86-97. doi: 10.1007/s11682-016-9507-8.

PMID:
26809289
47.

Is Breast Cancer a Curable Disease?

Hayes DF.

J Oncol Pract. 2016 Jan;12(1):13-6. doi: 10.1200/JOP.2015.009332. No abstract available.

PMID:
26759460
48.

Associations between genetic variants and the effect of letrozole and exemestane on bone mass and bone turnover.

Oesterreich S, Henry NL, Kidwell KM, Van Poznak CH, Skaar TC, Dantzer J, Li L, Hangartner TN, Peacock M, Nguyen AT, Rae JM, Desta Z, Philips S, Storniolo AM, Stearns V, Hayes DF, Flockhart DA.

Breast Cancer Res Treat. 2015 Nov;154(2):263-73. doi: 10.1007/s10549-015-3608-8. Epub 2015 Nov 4.

49.

Association of Variants in Candidate Genes with Lipid Profiles in Women with Early Breast Cancer on Adjuvant Aromatase Inhibitor Therapy.

Santa-Maria CA, Blackford A, Nguyen AT, Skaar TC, Philips S, Oesterreich S, Rae JM, Desta Z, Robarge J, Henry NL, Storniolo AM, Hayes DF, Blumenthal RS, Ouyang P, Post WS, Flockhart DA, Stearns V; Consortium on Breast Cancer Pharmacogenomics (COBRA).

Clin Cancer Res. 2016 Mar 15;22(6):1395-402. doi: 10.1158/1078-0432.CCR-15-1213. Epub 2015 Oct 13.

50.

Prospective Validation of a 21-Gene Expression Assay in Breast Cancer.

Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Perez EA, Olson JA Jr, Zujewski J, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Ravdin P, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Atkins JN, Berenberg JL, Sledge GW.

N Engl J Med. 2015 Nov 19;373(21):2005-14. doi: 10.1056/NEJMoa1510764. Epub 2015 Sep 27.

Supplemental Content

Loading ...
Support Center